apatinib and Sarcoma--Synovial

Synovial sarcoma is a rare malignant tumor. The role of apatinib in synovial sarcoma remains unclear. In this study, we aimed to determine the biological functions and the potential molecular mechanism of action of apatinib in synovial sarcoma.. SW982 cells were stimulated with apatinib. The relative expression of the genes was determined by performing qPCR. Protein levels were evaluated by western blot and immunohistochemistry assays. Proliferation, apoptosis, migration, and invasion of SW982 cells were determined by the CCK-8 assay, clone formation assay, flow cytometry, wound healing, and the transwell assay, respectively. Additionally, SW982 cells were injected into mice to induce synovial sarcoma.. Apatinib decreased the proliferation, migration, and invasion but increased the apoptosis of SW982 cells. Apatinib repressed tumor growth. Apatinib elevated miR-34a-5p and reduced HOXA13, leading to a significant decrease in proliferation, migration, and invasion, along with an enhancement of apoptosis in SW982 cells. Apatinib suppressed tumorigenesis and tumor growth in SW982 cells

Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Luciferases; Mice; MicroRNAs; RNA, Messenger; Sarcoma, Synovial

Apatinib is an oral tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2. It has been shown that apatinib is effective and safe for treatment of multiple solid tumors, including gastric cancer, liver cancer, non-small-cell lung cancer, and breast cancer. However, there is currently no consensus as to using Apatinib for the treatment of pleural synovial sarcoma, due to the rarity of primary pleural synovial sarcoma and lack of clinical studies as a consequence.. We reported here in the case of a 26-year-old Chinese woman diagnosed with pleural synovial sarcoma. She has undergone 2 surgeries, multiple regimens of chemotherapy and traditional Chinese medicine in other hospitals. Then the patient was admitted to our hospital with the compliant of chest pain and dyspnea. The medical history and available data supported the diagnosis of recurrence of pleural synovial sarcoma.. Due to the lack of efficacy of previous standard treatment, the patient was given apatinib and radiotherapy to relieve the symptoms. This patient achieved stable disease with apatinib at a dose of 500 mg/day. Her progression-free survival time was more than 7 months, and her overall survival was 8.5 months. Except for hand-foot syndrome, no grade 3 or 4 side effects were observed.. Apatinib may thus be an option for treatment of advanced synovial sarcoma after failure of other treatments. However, further study is needed to determine the efficacy of apatinib in pleural synovial sarcoma.

Topics: Adult; Fatal Outcome; Female; Humans; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Salvage Therapy; Sarcoma, Synovial

Primary pulmonary synovial sarcoma is a rare pulmonary malignant tumor originated from primitive mesenchymal, which has short overall survival and poor prognosis. Related case reports are lacked at home and abroad. In recent years, the development of targeted therapy has brought remarkable benefits to cancer patients. Apatinib (Hengrui Pharmaceutical Co. Ltd, Jiangsu, People's Republic of China) is a small molecule vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor, which selectively inhibits VEGFR-2 and blocks the VEGF signal pathway, then strongly inhibiting the tumor angiogenesis. Apatinib has shown favorable therapeutic effect and acceptable toxicity on various tumors. Here we report a case of primary pulmonary synovial sarcoma with postoperative multiple metastases treated with apatinib, in order to provide a new considerable treatment.
.. 【中文题目：阿帕替尼治疗肺原发性滑膜肉瘤
术后多发转移1例】 【中文摘要：原发性肺滑膜肉瘤是一种起源于原始间叶细胞的罕见肺部恶性肿瘤，其临床特点包括生存期短、预后差，目前国内外仅有少数相关报道。近年来，靶向治疗的发展为肿瘤患者带来显著的获益。甲磺酸阿帕替尼是我国自主研发的小分子血管内皮生长因子受体-2（vascular endothelial growth factor receptor-2, VEGFR-2）抑制剂，可高度选择性地抑制VEGFR-2酪氨酸激酶活性，阻断血管内皮生长因子（vascular endothelial growth factor, VEGF）结合后的信号通路，从而强效抑制肿瘤血管的生成，目前已在多种瘤种中显示出确切的抗肿瘤效果和可接受的毒副反应。本文介绍了阿帕替尼治疗原发性肺滑膜肉瘤术后多发转移1例，以期在临床工作中为医生提供新的治疗思路。
】 【中文关键词：甲磺酸阿帕替尼；肺肿瘤；原发性肺滑膜肉瘤】.

Topics: Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Postoperative Period; Pyridines; Sarcoma, Synovial